Workup of Cognitive Decline with Concurrent Balance Impairment

Initial Clinical Assessment

Obtain a comprehensive history from both the patient and a knowledgeable informant to capture cognitive changes, functional impairments, balance/gait problems, and neuropsychiatric symptoms. 1
Document key risk factors such as prior stroke/TIA, cardiovascular comorbidities (hypertension, diabetes, hyperlipidemia), use of anticholinergic or sedative‑hypnotic medications, depression or other psychiatric conditions, Parkinson’s disease, and recent head trauma. 3

Use the Montreal Cognitive Assessment (MoCA) as the primary screening tool because it is more sensitive than the MMSE for detecting mild cognitive impairment, especially when balance issues suggest vascular or atypical etiologies. 3
When time is limited, rapid screening alternatives include the Memory Impairment Screen + Clock Drawing Test, the Mini‑Cog, and the GP Assessment of Cognition (GPCOG). 5
Have the informant complete the AD8 or the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) to capture deficits the patient may not recognize. 3
Assess instrumental activities of daily living with the Pfeffer Functional Activities Questionnaire (FAQ) to objectively quantify functional loss. 3

Perform a dementia‑focused neurological exam that includes a Timed Up‑and‑Go test, Tinetti Balance Scale (or tandem walking), reflex assessment, orthostatic blood‑pressure measurement, and evaluation for focal neurological deficits. 6

Order routine laboratory studies in all patients: complete blood count with differential, comprehensive metabolic panel (including calcium, magnesium, liver enzymes), thyroid‑stimulating hormone, vitamin B12, homocysteine, and inflammatory markers (ESR, CRP). 1

Obtain a brain MRI (preferred over CT) to evaluate for vascular lesions, normal‑pressure hydrocephalus, subdural hematoma, other structural abnormalities, and characteristic patterns of atrophy. 2
Recommended MRI sequences: 3‑D T1 volumetric (coronal reformats for hippocampal assessment), FLAIR (white‑matter changes), T2 or susceptibility‑weighted imaging (SWI), and diffusion‑weighted imaging (DWI). 2
Apply semi‑quantitative scales when interpreting MRI: Medial Temporal Lobe Atrophy (MTA) scale, Fazekas scale for white‑matter disease, and Global Cortical Atrophy (GCA) scale. 2
If MRI is contraindicated, obtain a non‑contrast head CT with coronal reformations to assess hippocampal atrophy. 2

Refer to neurology, geriatrics, or a dementia specialist when the diagnosis remains unclear after the initial workup, when the presentation is atypical (e.g., early‑onset < 65 years, rapidly progressive, prominent behavioral change), when detailed neuropsychological testing is needed, when advanced biomarker testing (CSF analysis, amyloid or tau PET) is being considered, or when complex medical/psychiatric comorbidities exist. 1

Neuropsychological evaluation for detailed cognitive profiling. 1
Volumetric MRI for quantitative assessment of brain structures. 8
CSF biomarkers (Aβ42, total tau, phosphorylated tau) to detect Alzheimer’s disease pathology. 1
Amyloid PET or Tau PET when the diagnosis remains uncertain and the result would alter management. 9

Do not attribute combined cognitive decline and balance problems to “normal aging” without proper evaluation, as they often indicate specific treatable pathologies. 3
Do not rely solely on the MMSE in this population; it lacks sensitivity for vascular cognitive impairment and mild deficits. 3
Do not omit structural brain imaging; patients with both cognitive and balance issues have a higher likelihood of treatable structural causes such as normal‑pressure hydrocephalus or subdural hematoma. 2
Always obtain informant history; informant reports substantially improve diagnostic accuracy in cognitively impaired patients. 3